- Immune Modulation & Anti-Inflammatory Foundation
Thymosin Alpha-1
- Acts as a potent modulator of immunity and inflammation through interaction with toll-like receptors
- Controls immunity, tolerance and inflammation by regulating immune response via primary action on innate immune cells
- Dosing: 1.6mg SC daily for 1-2 bottles depending on response then consider 2 times a week for maintenance.
- Mechanism: Functions as a senolytic agent, immune modulation, upregulates glutathione, promotes cellular redox, and initiates IL-10 transcription
Thymosin Beta-4
- Has anti-inflammatory and anti-septic shock activities, inhibits TNF-α-induced NF-κB activation and IL-8 expression
- Promotes tissue repair, reduces inflammation, enhances wound healing, and promotes angiogenesis
- Dosing: 300 – 750 micrograms SC daily for 4-6 weeks then stop.
- Mechanism: Stops nuclear factor kappa beta (NF-κB) from transcribing pro-inflammatory cytokines, regulates immune cell function including T cells and macrophages
- Nerve Regeneration & Vascular Support
BPC-157 Injectable
- Has wound healing capability, increased collagen and new blood vessel formation, decreased inflammatory cell influx, and promotes healing of transected nerve injuries
- Demonstrated advanced healing and functional recovery in spinal cord compression, with rescue of somatosensory neurons in sciatic nerve after transection
- Dosing: 300 – 600 micrograms SC daily ongoing until improvements.
- Mechanism: Induces healing through angiogenesis (formation of new blood vessels), blocks molecules that inhibit growth and healing, increases growth receptors and upregulates anti-inflammatory proteins
- Neuroinflammation Management
GLP-1 Agonist
- GLP-1 receptor agonists have anti-inflammatory, neurotrophic, and neuroprotective properties in neurodegenerative disorder preclinical models
- Significantly reduce inflammation by modulating immune cell activity and suppressing pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, while inhibiting the NF-κB pathway
- In microglia, GLP-1R activation reduces neuroinflammation by modulating NF-κB activity, decreasing pro-inflammatory cytokines, and increasing anti-inflammatory markers like IL-10 and IL-4
- Dosing:
- Semaglutide: Start 0.12 mg weekly, titrate as tolerated – consider metabolic state of individual patient. Other GLP1 agonists can be considered here also.
Rationale: Addresses both metabolic factors and direct neuroinflammation
This multi-targeted approach addresses the inflammatory cascade, promotes nerve regeneration and angiogenesis, and tackles underlying metabolic dysfunction that may be perpetuating the condition.
.